Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment, Lung Cancer Treatments and Mutations, and Cancer Immunotherapy and Biomarkers.
Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer
Automated real-world data integration improves cancer outcome prediction
Impact of <i>Helicobacter pylori</i> infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial
Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers
A Novel Microbiome Signature in Gastric Cancer
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor–Amplified Gastroesophageal Cancer: Retrospective Global Experience
The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors
OncoTree: A Cancer Classification System for Precision Oncology
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Evaluation of the Association of Perioperative <i>UGT1A1</i> Genotype–Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma
Obtaining Knowledge in Pathology Reports Through a Natural Language Processing Approach With Classification, Named-Entity Recognition, and Relation-Extraction Heuristics
<i>FGFR2</i>-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i> -Amplified Gastroesophageal Adenocarcinoma
Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial
Pembrolizumab for Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma